Trials / Completed
CompletedNCT01069809
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Argos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.
Detailed description
The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AGS-004 | HIV-1 Immune Therapy |
| BIOLOGICAL | Placebo | Inactive Placebo Injection |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2014-08-01
- Completion
- 2015-09-01
- First posted
- 2010-02-17
- Last updated
- 2017-01-24
Locations
9 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01069809. Inclusion in this directory is not an endorsement.